Safety and pharmacokinetics study of a novel anti-PD-L1 therapeutic to improve immunotherapy in triple-negative breast cancer

Therapeutic Innovation Australia 2026 Open access

Read full text

Authors: Therapeutic Innovation Australia

DOI: 10.82292/jgzw-wk34

Cited by: 0

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Breast Cancer Treatment Studies Immunotherapy and Immune Responses